Omission of sentinel lymph node biopsy,
does it really help with De-escalation preserving five-year distant disease-free survival in small breast cancer with negative axillary ultrasonography?
research showsThe grade is B with 72 points. Five-year distant disease-free survival was 97.7% with sentinel lymph node biopsy and 98.0% with no axillary surgery, an absolute difference of +0.3 points for omission. The hazard ratio for omission versus biopsy was 0.84 (90% CI 0.45 to 1.54); its upper limit was within the prespecified noninferiority threshold of 1.74 (P=0.02). The benefit is de-escalation without worse survival, not evidence that biopsy itself is harmful.
ads claimThe supported statement is that omission was noninferior for five-year distant disease-free survival in selected patients. It is not supported to say that biopsy is harmful or that every small breast cancer can forgo nodal staging.
Useful facts when choosing a product
- Eligibility centered on tumors up to 2 cm, negative axillary ultrasonography, and planned breast-conserving surgery.
- Five-year cumulative axillary recurrence was 0.4% without surgery, but follow-up and adjuvant-treatment assessment remain necessary.
- Verdict 2345 is B with 76 points and asks whether adding adjuvant abemaciclib helps high-risk early breast cancer. This verdict asks whether staging surgery can be removed in selected lower-risk disease. The questions differ.
What the research actually shows
Eighteen centers in Italy, Switzerland, Spain, and Chile randomized 1,463 patients and analyzed 1,405. The paper defined distant disease-free survival events as "distant metastases and deaths from all causes." It specified "a margin of noninferiority for the 5-year DDFS of 2.5%" and required the upper 90% confidence limit for the hazard ratio to be "less than 1.74." Results were 97.7% versus 98.0%, HR 0.84 (90% CI 0.45 to 1.54).
Why this is classified as B (72)
The prespecified noninferiority margin was met for the hard-event endpoint of five-year distant disease-free survival, but this is a single noninferiority trial without independent replication, and the paper did not identify a study funding source, giving B with 72 points.
Counterpoint. Median follow-up was 5.7 years. Hormone receptor-positive disease can recur late, so longer follow-up and external replication are important.
Rejudgment record. Primary paper, protocol, and registration checked — Large multicenter noninferiority randomized trial of five-year distant disease-free survival
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Noninferior five-year distant disease-free survival with biopsy omission | B | The HR upper limit of 1.54 was within the prespecified 1.74 threshold. |
| Sentinel lymph node biopsy itself is harmful | ? | The demonstrated benefit is de-escalation while preserving survival. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Multicenter open-label active-controlled noninferiority randomized trial | 1,405 | No study funding source identified in the paper | Five-year distant disease-free survival with distant metastasis or death from any cause as events | 97.7% versus 98.0%, absolute difference +0.3 points for omission, HR 0.84 (90% CI 0.45 to 1.54); threshold HR 1.74, P=0.02 | Hard-outcome RCT; limited by noninferiority |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Axillary Ultrasonography: The SOUND Randomized Clinical Trial - Benefit — Evidence Grade B·72. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/omit-sentinel-node-biopsy-small-breast-cancer-sound/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.